Patents by Inventor David W. Osborne

David W. Osborne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220031705
    Abstract: The present invention is a method and composition comprising laureth-4 in topical formulations, wherein the laureth-4 increases the penetration of active ingredients across the skin. In a particularly preferred embodiment, the active ingredient is SHR0302.
    Type: Application
    Filed: July 27, 2021
    Publication date: February 3, 2022
    Applicant: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventor: David W. OSBORNE
  • Publication number: 20210386719
    Abstract: The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol monoethyl ether, and/or hexylene glycol.
    Type: Application
    Filed: August 13, 2021
    Publication date: December 16, 2021
    Applicant: ARCUTIS BIOTHERAPEUTICS, Inc.
    Inventors: David W. OSBORNE, Bhaskar CHAUDHURI, Archie W. THURSTON, JR.
  • Patent number: 11129818
    Abstract: The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol monoethyl ether, and/or hexylene glycol.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: September 28, 2021
    Assignee: Arcutis Biotherapeutics, Inc.
    Inventors: David W. Osborne, Bhaskar Chaudhuri, Archie W. Thurston, Jr.
  • Publication number: 20210275509
    Abstract: A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.
    Type: Application
    Filed: May 21, 2021
    Publication date: September 9, 2021
    Applicant: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventors: Howard WELGUS, Archie W. THURSTON, JR., David W. Osborne
  • Publication number: 20210244718
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Application
    Filed: November 23, 2020
    Publication date: August 12, 2021
    Applicant: ARCUTIS INC.
    Inventor: David W. Osborne
  • Publication number: 20210161870
    Abstract: An improved a method of treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.
    Type: Application
    Filed: February 5, 2021
    Publication date: June 3, 2021
    Applicant: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventors: Howard WELGUS, Archie THURSTON, David W. OSBORNE
  • Patent number: 10940142
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: March 9, 2021
    Assignee: Arcutis, Inc.
    Inventor: David W. Osborne
  • Publication number: 20200163944
    Abstract: The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol monoethyl ether, and/or hexylene glycol.
    Type: Application
    Filed: January 31, 2020
    Publication date: May 28, 2020
    Applicant: ARCUTIS, INC.
    Inventors: David W. OSBORNE, Bhaskar CLAUDHURI, Archie W. THURSTON, Jr.
  • Publication number: 20200155524
    Abstract: A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.
    Type: Application
    Filed: September 6, 2019
    Publication date: May 21, 2020
    Applicant: ARCUTIS, INC.
    Inventors: Howard WELGUS, Archie W. THURSTON, JR., David W. Osborne
  • Publication number: 20190365642
    Abstract: Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition. A shorter skin penetration lag time provides quicker onset of disease relief and more consistent bioavailability as there is less transference to clothing or other people. The skin penetration lag time for roflumilast can be reduced by formulating a roflumilast composition to have a pH between 4.0-6.5 and/or combining roflumilast with an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate.
    Type: Application
    Filed: May 30, 2019
    Publication date: December 5, 2019
    Applicant: ARCUTIS, INC.
    Inventor: David W. OSBORNE
  • Patent number: 10441530
    Abstract: The invention relates to pharmaceutical compositions and related methods for the topical administration of polar drugs. In a particular embodiment, the invention relates to a pharmaceutical composition comprising an active pharmaceutical agent that is a polar drug, such as potassium 2,5-dihydroxybenzenesulfonate, at least one occlusive agent, and at least one stabilizer.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: October 15, 2019
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: David W. Osborne, Pramod P. Sarpotdar, Arturo J. Angel, Inigo Saenz de Tejada Gorman, Pedro Cuevas Sànchez
  • Publication number: 20190091333
    Abstract: The low aqueous solubility of roflumilast in parenteral preparations and topical emulsions, suspensions, gels or solutions can be improved by including a blend of water-miscible solvents in the pharmaceutical composition. The blend of water-miscible solvents can include diethylene glycol monoethyl ether (Tradename Transcutol®; abbreviated DEGEE) and water. The ratio of diethylene glycol monoethyl ether to water is from 1:10 to 20:1. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Application
    Filed: September 22, 2017
    Publication date: March 28, 2019
    Applicant: ARCUTIS, INC.
    Inventor: David W. Osborne
  • Publication number: 20190015398
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Application
    Filed: September 20, 2018
    Publication date: January 17, 2019
    Applicant: ARCUTIS, INC.
    Inventor: David W. Osborne
  • Patent number: 10172841
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 8, 2019
    Assignee: ARCUTIS, INC.
    Inventor: David W. Osborne
  • Publication number: 20180353490
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Application
    Filed: December 20, 2017
    Publication date: December 13, 2018
    Applicant: ARCUTIS, INC.
    Inventor: David W. Osborne
  • Patent number: 10105354
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: October 23, 2018
    Assignee: Arcutis, Inc.
    Inventor: David W. Osborne
  • Publication number: 20180078495
    Abstract: The invention relates to pharmaceutical compositions and related methods for the topical administration of polar drugs. In a particular embodiment, the invention relates to a pharmaceutical composition comprising an active pharmaceutical agent that is a polar drug, such as potassium 2,5-dihydroxybenzenesulfonate, at least one occlusive agent, and at least one stabilizer.
    Type: Application
    Filed: September 6, 2017
    Publication date: March 22, 2018
    Inventors: David W. Osborne, Pramod P. Sarpotdar, Arturo J. Angel, Inigo Saenz de Tejada Gorman, Pedro Cuevas Sànchez
  • Patent number: 9907788
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: March 6, 2018
    Assignee: Arcutis Inc.
    Inventor: David W. Osborne
  • Patent number: 9895359
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in patient in need of such treatment.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: February 20, 2018
    Assignee: ARCUTIS, INC.
    Inventor: David W. Osborne
  • Patent number: 9884050
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: February 6, 2018
    Assignee: Arcutis, Inc.
    Inventor: David W. Osborne